JP2024506385A5 - - Google Patents

Info

Publication number
JP2024506385A5
JP2024506385A5 JP2023548874A JP2023548874A JP2024506385A5 JP 2024506385 A5 JP2024506385 A5 JP 2024506385A5 JP 2023548874 A JP2023548874 A JP 2023548874A JP 2023548874 A JP2023548874 A JP 2023548874A JP 2024506385 A5 JP2024506385 A5 JP 2024506385A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
gdc
patient
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023548874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506385A (ja
JP7904849B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016270 external-priority patent/WO2022177844A1/en
Publication of JP2024506385A publication Critical patent/JP2024506385A/ja
Publication of JP2024506385A5 publication Critical patent/JP2024506385A5/ja
Application granted granted Critical
Publication of JP7904849B2 publication Critical patent/JP7904849B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023548874A 2021-02-16 2022-02-14 Gdc-9545及びgdc-0077を含む併用療法を使用する乳がんの治療 Active JP7904849B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149944P 2021-02-16 2021-02-16
US63/149,944 2021-02-16
PCT/US2022/016270 WO2022177844A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077

Publications (3)

Publication Number Publication Date
JP2024506385A JP2024506385A (ja) 2024-02-13
JP2024506385A5 true JP2024506385A5 (cg-RX-API-DMAC7.html) 2025-02-18
JP7904849B2 JP7904849B2 (ja) 2026-08-13

Family

ID=80953424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548874A Active JP7904849B2 (ja) 2021-02-16 2022-02-14 Gdc-9545及びgdc-0077を含む併用療法を使用する乳がんの治療

Country Status (8)

Country Link
US (1) US20230381155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294395B1 (cg-RX-API-DMAC7.html)
JP (1) JP7904849B2 (cg-RX-API-DMAC7.html)
CN (1) CN117377472A (cg-RX-API-DMAC7.html)
ES (1) ES3030540T3 (cg-RX-API-DMAC7.html)
PL (1) PL4294395T3 (cg-RX-API-DMAC7.html)
TW (1) TWI808648B (cg-RX-API-DMAC7.html)
WO (1) WO2022177844A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538147A (ja) * 2022-11-02 2025-11-26 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリックポケット及びオルソステリックポケットの標的化
JP2025163068A (ja) * 2022-11-02 2025-10-28 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリックポケット及びオルソステリックポケットの標的化

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP3863618A1 (en) * 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
MX2022010425A (es) * 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.

Similar Documents

Publication Publication Date Title
JP2024015120A5 (cg-RX-API-DMAC7.html)
JP2022022264A5 (cg-RX-API-DMAC7.html)
JP2023174661A5 (cg-RX-API-DMAC7.html)
JP2022009090A5 (cg-RX-API-DMAC7.html)
JP2007515469A5 (cg-RX-API-DMAC7.html)
JP2022544485A5 (cg-RX-API-DMAC7.html)
JP2020517696A5 (cg-RX-API-DMAC7.html)
JP2025509510A5 (cg-RX-API-DMAC7.html)
JP2012522837A5 (cg-RX-API-DMAC7.html)
JP2019508476A5 (cg-RX-API-DMAC7.html)
JP2018503610A5 (cg-RX-API-DMAC7.html)
JP2023522415A5 (cg-RX-API-DMAC7.html)
CN115135649A (zh) 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
JP2024054117A5 (cg-RX-API-DMAC7.html)
CN109985237A (zh) 一种治疗结直肠癌的药物组合物及其应用
JP2021169534A5 (cg-RX-API-DMAC7.html)
JP2022523045A5 (cg-RX-API-DMAC7.html)
JP2024514112A5 (cg-RX-API-DMAC7.html)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2023531930A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2025511401A5 (cg-RX-API-DMAC7.html)
JP2022543679A5 (cg-RX-API-DMAC7.html)
JP2025509278A5 (cg-RX-API-DMAC7.html)
JP2024529430A5 (cg-RX-API-DMAC7.html)